Tapewire

Nasdaq · USD

CLYM

Climb Bio, Inc.

Export transactions ↓
Tapewire entity
5064
SEC CIK
0001768446
Parsed reports
119

Last 12 months

Inside the activity.

3 purchase rows · 6 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202520
Jan 202610
Feb 202604
Mar 202600
Apr 202600
May 202600
Jun 202601
Jul 202600
Aug 202600
Sep 202601
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
September 28, 2026 Filed Oct 1, 2026 00:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
Exercise / conversionStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $1.29 $0.00
Disclosure

SEC source: 0001231919-26-001416 · form4-09302026_080936.xml · derivative · entry 13

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2026-09-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Immediately exercisable.

F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
September 28, 2026 Filed Oct 1, 2026 00:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
Exercise / conversionStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $7.89 $0.00
Disclosure

SEC source: 0001231919-26-001416 · form4-09302026_080936.xml · derivative · entry 12

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2026-09-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Immediately exercisable.

F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
September 28, 2026 Filed Oct 1, 2026 00:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
Exercise / conversionStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $3.00 $0.00
Disclosure

SEC source: 0001231919-26-001416 · form4-09302026_080936.xml · derivative · entry 11

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2026-09-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Immediately exercisable.

F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
September 28, 2026 Filed Oct 1, 2026 00:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
Exercise / conversionStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $3.46 $0.00
Disclosure

SEC source: 0001231919-26-001416 · form4-09302026_080936.xml · derivative · entry 10

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2026-09-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Immediately exercisable.

F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
September 28, 2026 Filed Oct 1, 2026 00:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
Exercise / conversionCommon Stock 40,000 $1.29 $51,600.00
Disclosure

SEC source: 0001231919-26-001416 · form4-09302026_080936.xml · nonDerivative · entry 4

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 70,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
September 28, 2026 Filed Oct 1, 2026 00:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
Exercise / conversionCommon Stock 10,000 $7.89 $78,900.00
Disclosure

SEC source: 0001231919-26-001416 · form4-09302026_080936.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 30,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
September 28, 2026 Filed Oct 1, 2026 00:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
Exercise / conversionCommon Stock 10,000 $3.00 $30,000.00
Disclosure

SEC source: 0001231919-26-001416 · form4-09302026_080936.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 20,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
September 28, 2026 Filed Oct 1, 2026 00:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
Exercise / conversionCommon Stock 10,000 $3.46 $34,600.00
Disclosure

SEC source: 0001231919-26-001416 · form4-09302026_080936.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
September 15, 2026 Filed Sep 17, 2026 20:15 UTC SaleCommon Stock 100,000 $13.67 $1,366,820.00
Disclosure

SEC source: 0001193125-26-394357 · ownership.xml · nonDerivative · entry 1

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 467,969

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2026.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.3800 to $14.3400, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 413,312 shares of the issuer's common stock, par value $0.0001 per share, distributed by Sera Medicines, LLC to certain of its limited partners, including the reporting person, for no consideration in a pro-rata in-kind distribution.

Read SEC document
June 29, 2026 Filed Jun 30, 2026 23:50 UTC
Brennan AoifeDirector · President and CEO
SaleCommon Stock 30,902 $13.17 $406,979.34
Disclosure

SEC source: 0001193125-26-291131 · ownership.xml · nonDerivative · entry 2

Brennan Aoife · CIK 0001714563 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,731

F3 · kind: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Read SEC document
June 29, 2026 Filed Jul 1, 2026 21:45 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
GrantStock Option (Right to Buy) · Derivative 70,284 $0.00 Strike: $13.36 $0.00
Disclosure

SEC source: 0001231919-26-000722 · form4-07012026_090743.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 70,284

Underlying: Common Stock · 70,284 shares

Expires 2036-06-29

F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments from June 29, 2026 (the "Vesting Commencement Date") until the third anniversary of the Vesting Commencement Date, subject to Ms. Celebi's continued service through such date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Under Ms. Celebi's arrangement with the Adviser, Ms. Celebi holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Ms. Celebi is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
June 29, 2026 Filed Jul 1, 2026 20:30 UTC GrantStock Option (Right to Buy) · Derivative 70,284 $0.00 Strike: $13.36 $0.00
Disclosure

SEC source: 0001193125-26-292640 · ownership.xml · derivative · entry 1

Celebi Breanna Maurine · CIK 0002137903 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,284

Underlying: Common Stock · 70,284 shares

Expires 2036-06-29

F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments from June 29, 2026 (the "Vesting Commencement Date") until the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such date.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.

Read SEC document
June 27, 2026 Filed Jun 30, 2026 23:50 UTC
Brennan AoifeDirector · President and CEO
Exercise / conversionRestricted Stock Units · Derivative 68,750 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-291131 · ownership.xml · derivative · entry 3

Brennan Aoife · CIK 0001714563 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 137,500

Underlying: Common Stock · 68,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

F6 · derivative.expiration_date: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

Read SEC document
June 27, 2026 Filed Jun 30, 2026 23:50 UTC
Brennan AoifeDirector · President and CEO
Exercise / conversionCommon Stock 68,750 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-291131 · ownership.xml · nonDerivative · entry 1

Brennan Aoife · CIK 0001714563 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,633

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock

F2 · balance_after: Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan.

Read SEC document
June 05, 2026 Filed Jun 8, 2026 22:26 UTC
Dunn JudithDirector
GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $10.55 $0.00
Disclosure

SEC source: 0001193125-26-262270 · ownership.xml · derivative · entry 1

Dunn Judith · CIK 0001811904 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Read SEC document
June 05, 2026 Filed Jun 8, 2026 22:28 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $10.55 $0.00
Disclosure

SEC source: 0001193125-26-262273 · ownership.xml · derivative · entry 1

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Read SEC document
June 05, 2026 Filed Jun 8, 2026 18:34 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $10.55 $0.00
Disclosure

SEC source: 0001193125-26-262281 · ownership.xml · derivative · entry 1

Cumbo Alexander · CIK 0001685994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Read SEC document
June 05, 2026 Filed Jun 8, 2026 18:37 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $10.55 $0.00
Disclosure

SEC source: 0001193125-26-262287 · ownership.xml · derivative · entry 1

WILLIAMS DOUGLAS E · CIK 0001184847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Read SEC document
June 05, 2026 Filed Jun 8, 2026 22:57 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $10.55 $0.00
Disclosure

SEC source: 0001231919-26-000610 · form4-06082026_100640.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to Dr. Andrew Levin's continuous service through such date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
June 05, 2026 Filed Jun 8, 2026 22:39 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $10.55 $0.00
Disclosure

SEC source: 0001193125-26-262290 · ownership.xml · derivative · entry 1

Drapkin Kimberlee C · CIK 0001340881 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Read SEC document
June 05, 2026 Filed Jun 8, 2026 22:42 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $10.55 $0.00
Disclosure

SEC source: 0001193125-26-262292 · ownership.xml · derivative · entry 1

Levin Andrew David · CIK 0001867539 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

F2 · ownership.direct: Under the reporting person's arrangement with RA Capital Management, L.P. (the "Adviser"), the reporting person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The reporting person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The reporting person therefore disclaims beneficial ownership of the stock option and underlying common stock.

Read SEC document
April 29, 2026 Filed Apr 29, 2026 22:46 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund III, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
GrantPre-Funded Warrants (Right to Buy) · Derivative 2,106,000 $9.50 Strike: $0.00 $20,006,789.40
Disclosure

SEC source: 0001231919-26-000429 · form4-04292026_100401.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 22,546,000

Underlying: Common Stock · 2,106,000 shares

Expires not disclosed

F1 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F1 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

Read SEC document
February 26, 2026 Filed Feb 27, 2026 21:05 UTC SaleCommon Stock 16,313 $7.01 $114,288.88
Disclosure

SEC source: 0001193125-26-082533 · ownership.xml · nonDerivative · entry 2

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 154,657

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0400, inclusive.

Read SEC document
February 25, 2026 Filed Feb 27, 2026 21:05 UTC SaleCommon Stock 33,687 $7.00 $235,963.96
Disclosure

SEC source: 0001193125-26-082533 · ownership.xml · nonDerivative · entry 1

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 170,970

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0600, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.

Read SEC document
February 13, 2026 Filed Feb 17, 2026 21:05 UTC SaleCommon Stock 10,000 $5.81 $58,141.00
Disclosure

SEC source: 0001193125-26-054568 · ownership.xml · nonDerivative · entry 2

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 204,657

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.6200 to $6.1200, inclusive.

Read SEC document
February 12, 2026 Filed Feb 17, 2026 21:05 UTC SaleCommon Stock 90,000 $5.23 $470,988.00
Disclosure

SEC source: 0001193125-26-054568 · ownership.xml · nonDerivative · entry 1

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 214,657

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.2212 to $5.2481, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.

Read SEC document
January 06, 2026 Filed Jan 8, 2026 16:05 UTC
ALTSCHULLER SusanChief Financial Officer
GrantStock Option (Right to Buy) · Derivative 142,500 $0.00 Strike: $3.81 $0.00
Disclosure

SEC source: 0001193125-26-007665 · ownership.xml · derivative · entry 1

ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,500

Underlying: Common Stock · 142,500 shares

Expires 2036-01-05

F1 · derivative.exercise_date: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service.

Read SEC document
January 06, 2026 Filed Jan 8, 2026 16:05 UTC
Wilson Perrin MeganChief Business Officer
GrantStock Option (Right to Buy) · Derivative 300,000 $0.00 Strike: $3.81 $0.00
Disclosure

SEC source: 0001193125-26-007667 · ownership.xml · derivative · entry 1

Wilson Perrin Megan · CIK 0002074091 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2036-01-05

F1 · derivative.exercise_date: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service.

Read SEC document
January 06, 2026 Filed Jan 8, 2026 21:05 UTC
Brennan AoifeDirector · President and CEO
GrantStock Option (Right to Buy) · Derivative 700,000 $0.00 Strike: $3.81 $0.00
Disclosure

SEC source: 0001193125-26-007670 · ownership.xml · derivative · entry 1

Brennan Aoife · CIK 0001714563 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2036-01-05

F1 · derivative.exercise_date: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service.

Read SEC document
January 06, 2026 Filed Jan 8, 2026 16:05 UTC
Driscoll CindySenior Vice President, Finance
GrantStock Option (Right to Buy) · Derivative 100,000 $0.00 Strike: $3.81 $0.00
Disclosure

SEC source: 0001193125-26-007662 · ownership.xml · derivative · entry 1

Driscoll Cindy · CIK 0001741269 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2036-01-05

F1 · derivative.exercise_date: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service.

Read SEC document
January 05, 2026 Filed Jan 7, 2026 21:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund III, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
PurchaseCommon Stock 7,111 $3.50 $24,888.50
Disclosure

SEC source: 0001231919-26-000018 · form4-01072026_090137.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,403,429

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.495 to $3.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

Read SEC document
December 12, 2025 Filed Dec 16, 2025 00:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund III, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
PurchaseCommon Stock 101,462 $2.86 $290,181.32
Disclosure

SEC source: 0001231919-25-000616 · form4-12162025_121255.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,396,318

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.32 to $3.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

Read SEC document
December 11, 2025 Filed Dec 16, 2025 00:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund III, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
GrantPre-Funded Warrants (Right to Buy) · Derivative 20,440,000 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0001231919-25-000616 · form4-12162025_121255.xml · derivative · entry 9

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 20,440,000

Underlying: Common Stock · 20,440,000 shares

Expires not disclosed

F1 · kind: On December 11, 2025, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 20,440,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 20,440,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share.

F1 · price: On December 11, 2025, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 20,440,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 20,440,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share.

F11 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F11 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

Read SEC document
December 11, 2025 Filed Dec 16, 2025 00:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund III, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
PurchaseCommon Stock 213,099 $2.18 $464,555.82
Disclosure

SEC source: 0001231919-25-000616 · form4-12162025_121255.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,294,856

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.11 to $2.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

Read SEC document
December 11, 2025 Filed Dec 16, 2025 00:55 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund III, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
Disposition to issuerCommon Stock 20,440,000 $0.00 $0.00
Disclosure

SEC source: 0001231919-25-000616 · form4-12162025_121255.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,081,757

F1 · kind: On December 11, 2025, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 20,440,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 20,440,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share.

F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

Read SEC document
October 01, 2025 Filed Oct 1, 2025 17:52 UTC
ALTSCHULLER SusanChief Financial Officer
GrantStock Option (Right to Buy) · Derivative 600,000 $0.00 Strike: $1.97 $0.00
Disclosure

SEC source: 0001193125-25-227099 · ownership.xml · derivative · entry 1

ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires 2035-09-30

F1 · derivative.exercise_date: This option was granted on October 1, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date, and the remainder are scheduled to vest in 36 equal monthly installments through October 1, 2029, subject to the Reporting Person's continued service.

Read SEC document
August 07, 2025 Filed Aug 11, 2025 20:15 UTC GrantCommon Stock 100,375 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-106563 · ownership.xml · nonDerivative · entry 1

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 304,657

F1 · shares: On June 27, 2024, the reporting person was granted restricted stock units ("RSUs") to acquire a total of 100,375 shares of common stock that vested based on the achievement of certain performance-based milestones and subject to continuous service. On August 7, 2025, the milestones were deemed to be achieved, resulting in the vesting of the RSUs as to all 100,375 shares.

Read SEC document
June 30, 2025 Filed Jul 1, 2025 20:37 UTC
Brennan AoifeDirector · President and CEO
SaleCommon Stock 20,618 $1.22 $25,153.96
Disclosure

SEC source: 0000950170-25-092284 · ownership.xml · nonDerivative · entry 2

Brennan Aoife · CIK 0001714563 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,132

F2 · kind: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.20 to $1.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Read SEC document
June 27, 2025 Filed Jul 1, 2025 20:32 UTC Exercise / conversionRestricted Stock Units · Derivative 25,094 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-092273 · ownership.xml · derivative · entry 2

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,094 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: The RSUs were granted on June 27, 2024 and vested as to 50% of the shares on January 1, 2025, vested as to 25% of the shares on March 27, 2025 and vested as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.

F3 · derivative.expiration_date: The RSUs were granted on June 27, 2024 and vested as to 50% of the shares on January 1, 2025, vested as to 25% of the shares on March 27, 2025 and vested as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.

Read SEC document
June 27, 2025 Filed Jul 1, 2025 20:32 UTC Exercise / conversionCommon Stock 25,094 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-092273 · ownership.xml · nonDerivative · entry 1

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 204,282

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.

Read SEC document
June 27, 2025 Filed Jul 1, 2025 20:37 UTC
Brennan AoifeDirector · President and CEO
Exercise / conversionRestricted Stock Units · Derivative 68,750 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-092284 · ownership.xml · derivative · entry 3

Brennan Aoife · CIK 0001714563 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 206,250

Underlying: Common Stock · 68,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

F5 · derivative.expiration_date: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

Read SEC document
June 27, 2025 Filed Jul 1, 2025 20:37 UTC
Brennan AoifeDirector · President and CEO
Exercise / conversionCommon Stock 68,750 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-092284 · ownership.xml · nonDerivative · entry 1

Brennan Aoife · CIK 0001714563 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.

Read SEC document
June 20, 2025 Filed Jun 20, 2025 20:20 UTC
Pimblett EmilySVP, Finance & CAO
SaleCommon Stock 1,242 $1.24 $1,540.08
Disclosure

SEC source: 0000950170-25-088524 · ownership.xml · nonDerivative · entry 2

Pimblett Emily · CIK 0001969365 · SVP, Finance & CAO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,888

F2 · kind: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 27, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.

Read SEC document
June 18, 2025 Filed Jun 20, 2025 20:20 UTC
Pimblett EmilySVP, Finance & CAO
Exercise / conversionRestricted Stock Units · Derivative 5,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-088524 · ownership.xml · derivative · entry 3

Pimblett Emily · CIK 0001969365 · SVP, Finance & CAO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.

F4 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.

Read SEC document
June 18, 2025 Filed Jun 20, 2025 20:20 UTC
Pimblett EmilySVP, Finance & CAO
Exercise / conversionCommon Stock 5,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-088524 · ownership.xml · nonDerivative · entry 1

Pimblett Emily · CIK 0001969365 · SVP, Finance & CAO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,130

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.

Read SEC document
June 17, 2025 Filed Jun 20, 2025 16:20 UTC
Driscoll CindySenior Vice President, Finance
GrantStock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $1.20 $0.00
Disclosure

SEC source: 0000950170-25-088525 · ownership.xml · derivative · entry 1

Driscoll Cindy · CIK 0001741269 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2035-06-16

F1 · derivative.exercise_date: This option was granted on June 17, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through June 17, 2029, subject to the Reporting Person's continued service.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 20:11 UTC
Dunn JudithDirector
GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $1.29 $0.00
Disclosure

SEC source: 0000950170-25-082323 · ownership.xml · derivative · entry 1

Dunn Judith · CIK 0001811904 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 20:10 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $1.29 $0.00
Disclosure

SEC source: 0000950170-25-082320 · ownership.xml · derivative · entry 1

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 16:11 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $1.29 $0.00
Disclosure

SEC source: 0000950170-25-082324 · ownership.xml · derivative · entry 1

Cumbo Alexander · CIK 0001685994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 16:11 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $1.29 $0.00
Disclosure

SEC source: 0000950170-25-082322 · ownership.xml · derivative · entry 1

WILLIAMS DOUGLAS E · CIK 0001184847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.